Document ID: FDA-2004-D-0298-0004
Agency: fda
Document Type: Notice
Title: Compliance Policy Guide; Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs; Notice to Extend Expiration Date
Posted Date: 2008-12-22T05:00Z

[Federal Register: December 22, 2008 (Volume 73, Number 246)]
[Notices]
[Page 78371]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr22de08-89]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2004-D-0298] (formerly Docket No. 2004D-0499)

Compliance Policy Guide; Radiofrequency Identification
Feasibility Studies and Pilot Programs for Drugs; Notice to Extend
Expiration Date

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; extension of expiration date.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is extending the
expiration date of compliance policy guide (CPG) Sec. 400.210 entitled
``Radiofrequency Identification (RFID) Feasibility Studies and Pilot
Programs for Drugs'' to December 31, 2010.

FOR FURTHER INFORMATION CONTACT: Ilisa Bernstein, Office of the
Commissioner, Office of Policy, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 1, rm. 4341, Silver Spring, MD 20993-0002, 301-
796-4830.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 17, 2004
(69 FR 67360), FDA announced the availability of CPG Sec. 400.210
entitled ``Radiofrequency Identification (RFID) Feasibility Studies and
Pilot Programs for Drugs.'' FDA has identified RFID as a promising
technology to be used in the various efforts to combat counterfeit
drugs. The CPG describes how the agency intends to exercise its
enforcement discretion regarding certain regulatory requirements that
might otherwise be applicable to studies involving RFID technology for
drugs. The goal of the CPG is to facilitate performance of RFID studies
and to allow industry to gain experience with the use of RFID
technology and its effect on the long-term safety and integrity of the
U.S. drug supply.
    On September 27, 2007, the Food and Drug Administration Amendments
Act of 2007 (FDAAA) was signed into law. Section 913 of FDAAA addresses
pharmaceutical safety and creates section 505D of the Federal Food,
Drug, and Cosmetic Act (the act). Section 505D(b) of the act requires
the development of standards for the identification, validation,
authentication, and tracking and tracing of prescription drugs. Section
505D(b)(3) of the act states that these new standards shall address
promising technologies, which may include RFID technology.
    In implementing section 505D of the act, FDA is currently
addressing issues, such as promising technologies, that are relevant
also for the CPG. In addition, FDA is considering further the
experience of stakeholders and the agency under the CPG. As we consider
all of these issues, the CPG will remain in effect until December 31,
2010.

    Dated: December 16, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-30297 Filed 12-19-08; 8:45 am]

BILLING CODE 4160-01-S